These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 20053775)

  • 21. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma.
    Tanaka E; Hashimoto Y; Ito T; Kondo K; Higashiyama M; Tsunoda S; Ortiz C; Sakai Y; Inazawa J; Shimada Y
    Clin Cancer Res; 2007 Feb; 13(4):1331-40. PubMed ID: 17317845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
    Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
    Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
    VanderPorten EC; Taverna P; Hogan JN; Ballinger MD; Flanagan WM; Fucini RV
    Mol Cancer Ther; 2009 Apr; 8(4):930-9. PubMed ID: 19372566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
    Chowdhury A; Chowdhury S; Tsai MY
    Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
    Shionome Y; Yan L; Liu S; Saeki T; Ouchi T
    PLoS One; 2013; 8(1):e55457. PubMed ID: 23383195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
    Jani JP; Arcari J; Bernardo V; Bhattacharya SK; Briere D; Cohen BD; Coleman K; Christensen JG; Emerson EO; Jakowski A; Hook K; Los G; Moyer JD; Pruimboom-Brees I; Pustilnik L; Rossi AM; Steyn SJ; Su C; Tsaparikos K; Wishka D; Yoon K; Jakubczak JL
    Mol Cancer Ther; 2010 Apr; 9(4):883-94. PubMed ID: 20354118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.
    Xie H; Lee MH; Zhu F; Reddy K; Peng C; Li Y; Lim DY; Kim DJ; Li X; Kang S; Li H; Ma W; Lubet RA; Ding J; Bode AM; Dong Z
    Cancer Res; 2013 Jan; 73(2):716-24. PubMed ID: 23117881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
    Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
    Romanelli A; Clark A; Assayag F; Chateau-Joubert S; Poupon MF; Servely JL; Fontaine JJ; Liu X; Spooner E; Goodstal S; de Cremoux P; Bièche I; Decaudin D; Marangoni E
    Mol Cancer Ther; 2012 Dec; 11(12):2693-703. PubMed ID: 23012245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora kinase inhibitors as anticancer molecules.
    Katayama H; Sen S
    Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.